In EBV-DLBCL, LAG-3 and TIM-3 might interact to balance the high level of immunosuppression in the tumor microenvironment (TME) with the increased level of immune checkpoints and tumor-associated macrophages, thus affecting the survival rate [48]. This evidence concerns the gene HAVCR2 and diffuse large B-cell lymphoma.